Case-fatality rate of invasive pneumococcal disease caused by various serotypes-an analysis of nationwide surveillance data from Israel, 2009-2018.

Objectives: The 20-valent pneumococcal conjugate vaccine (PCV20) has been introduced in Israel. Its public health benefit depends on its effect on mortality caused by PCV20 serotypes not present in 13-valent pneumococcal conjugate vaccine (PCV13) (PCV20non13). We aimed to describe invasive pneumococcal disease (IPD) characteristics and case-fatality rate (CFR) among adults by serotypes.